Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | Chf Ops Off, Pres, Informatics | February 21, 2025 | February 25, 2025 |
| SomaLogic, Inc.SLGC · Entity 95310 | President and COO | March 01, 2022 | March 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date February 21, 2025 · Filed February 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,811 |
Reported balance
After 2025-02-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-02-23 · Exercise / conversion · Acquired 8,443 · Balance 111,811 F1: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. F2: This balance includes 548 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan. The shares were acquired in transactions exempt from Section 16b-3. |
| Common StockSEC Table I · non-derivative | Direct | 109,755 |
Reported balance
After 2025-02-23 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-02-23 · Tax withholding · Disposed 2,056 · Balance 109,755 F3: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2035-02-21 | Direct | 143,266 |
Reported balance
After 2025-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-21 · Grant · Acquired 143,266 · Balance 143,266 F4: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. F5: On February 21, 2025, Ms. Harris was granted 143,266 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2034-02-23 | Direct | 42,344 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 42,344 F13: On February 23, 2024, Ms. Harris was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.96 · Expires 2034-05-02 | Direct | 19,984 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 19,984 F15: On May 2, 2024, Ms. Harris was granted 19,984 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 84,317 |
Reported balance
After 2025-02-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-21 · Grant · Acquired 84,317 · Balance 84,317 F6: On February 21, 2025, Ms. Harris was granted 84,317 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F7: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,886 |
Reported balance
After 2025-02-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-23 · Exercise / conversion · Disposed 8,443 · Balance 16,886 F8: On February 23, 2024, Ms. Harris was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F7: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 14,136 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 14,136 F11: On May 11, 2023, Ms. Harris was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F7: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 11,939 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 11,939 F17: On May 2, 2024, Ms. Harris was granted 11,939 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F7: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 59,382 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 59,382 F7: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.24 · Expires 2030-01-01 | Direct | 201,613 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 201,613 F9: On January 1, 2023, Ms. Harris was granted 201,613 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.65 · Expires 2030-05-11 | Direct | 39,683 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 39,683 F10: On May 11, 2023, Ms. Harris was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 21,204 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 21,204 F12: On May 11, 2023, Ms. Harris was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to theperformance criteria is31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stockover the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company. F7: Once vested, the shares of common stock are not subject to expiration. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 25,330 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 25,330 F14: On February 23, 2024, Ms. Harris was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant tothe performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company'scommon stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based onthe achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F7: Once vested, the shares of common stock are not subject to expiration. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 11,939 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 11,939 F16: On May 2, 2024, Ms. Harris was granted 11,939 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to theperformance criteria is17,909. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company'scommon stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based onthe achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F7: Once vested, the shares of common stock are not subject to expiration. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
F2: This balance includes 548 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan. The shares were acquired in transactions exempt from Section 16b-3.
F3: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
F4: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
F5: On February 21, 2025, Ms. Harris was granted 143,266 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F6: On February 21, 2025, Ms. Harris was granted 84,317 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F7: Once vested, the shares of common stock are not subject to expiration.
F8: On February 23, 2024, Ms. Harris was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F9: On January 1, 2023, Ms. Harris was granted 201,613 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F10: On May 11, 2023, Ms. Harris was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F11: On May 11, 2023, Ms. Harris was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F12: On May 11, 2023, Ms. Harris was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to theperformance criteria is31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stockover the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
F13: On February 23, 2024, Ms. Harris was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date
F14: On February 23, 2024, Ms. Harris was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant tothe performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company'scommon stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based onthe achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
F15: On May 2, 2024, Ms. Harris was granted 19,984 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F16: On May 2, 2024, Ms. Harris was granted 11,939 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to theperformance criteria is17,909. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company'scommon stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based onthe achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
F17: On May 2, 2024, Ms. Harris was granted 11,939 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
SomaLogic, Inc.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,125 |
Reported balance
After 2022-03-01 transaction · row 1
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 48,125 · Balance 48,125 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2032-02-29 | Direct | 288,750 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 288,750 · Balance 288,750 F1: 25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2025 Filed Feb 25, 2025 21:40 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 8,443 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000042 · wk-form4_1740519619.xml · derivative · entry 5 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,886 Underlying: Common Stock · 8,443 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: On February 23, 2024, Ms. Harris was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F7 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:40 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000042 · wk-form4_1740519619.xml · nonDerivative · entry 2 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,755 F3 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:40 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 8,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000042 · wk-form4_1740519619.xml · nonDerivative · entry 1 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. F2 · balance_after: This balance includes 548 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:40 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 84,317 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000042 · wk-form4_1740519619.xml · derivative · entry 4 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,317 Underlying: Common Stock · 84,317 shares Expires not disclosed F6 · derivative.exercise_date: On February 21, 2025, Ms. Harris was granted 84,317 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F7 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:40 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 143,266 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001077183-25-000042 · wk-form4_1740519619.xml · derivative · entry 3 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,266 Underlying: Common Stock · 143,266 shares Expires 2035-02-21 F4 · derivative.exercise_price: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. F5 · derivative.exercise_date: On February 21, 2025, Ms. Harris was granted 143,266 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 21:12 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 59,382 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000018 · wk-form4_1737061934.xml · derivative · entry 2 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,382 Underlying: Common Stock · 59,382 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 7,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000002 · wk-form4_1735938679.xml · nonDerivative · entry 1 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,820 F1 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the January 1, 2025 vesting of restricted stock. F2 · balance_after: This balance includes 1,589 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 7,068 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000071 · wk-form4_1715737076.xml · derivative · entry 3 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,136 Underlying: Common Stock · 7,068 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On May 11, 2023, Ms. Harris was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 1,722 | $14.86 | $25,588.92 |
DisclosureSEC source: 0001077183-24-000071 · wk-form4_1715737076.xml · nonDerivative · entry 2 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,301 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 7,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000071 · wk-form4_1715737076.xml · nonDerivative · entry 1 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:09 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantPerformance Stock Unit · Derivative | 11,939 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000060 · wk-form4_1714766939.xml · derivative · entry 11 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,939 Underlying: Common Stock · 11,939 shares Expires not disclosed F11 · derivative.exercise_date: On May 2, 2024, Ms. Harris was granted 11,939 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 17,909. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:09 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 11,939 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000060 · wk-form4_1714766939.xml · derivative · entry 10 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,939 Underlying: Common Stock · 11,939 shares Expires not disclosed F10 · derivative.exercise_date: On May 2, 2024, Ms. Harris was granted 11,939 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:09 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 19,984 | $0.00 Strike: $13.96 | $0.00 |
DisclosureSEC source: 0001077183-24-000060 · wk-form4_1714766939.xml · derivative · entry 9 Harris Melody · CIK 0001880847 · Chf Ops Off, Pres, Informatics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,984 Underlying: Common Stock · 19,984 shares Expires 2034-05-02 F9 · derivative.exercise_date: On May 2, 2024, Ms. Harris was granted 19,984 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantPerformance Stock Unit · Derivative | 25,330 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000027 · wk-form4_1709069261.xml · derivative · entry 8 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,330 Underlying: Common Stock · 25,330 shares Expires not disclosed F8 · derivative.exercise_date: On February 23, 2024, Ms. Harris was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 25,329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000027 · wk-form4_1709069261.xml · derivative · entry 7 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,329 Underlying: Common Stock · 25,329 shares Expires not disclosed F7 · derivative.exercise_date: On February 23, 2024, Ms. Harris was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 42,344 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000027 · wk-form4_1709069261.xml · derivative · entry 6 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,344 Underlying: Common Stock · 42,344 shares Expires 2034-02-23 F6 · derivative.exercise_date: On February 23, 2024, Ms. Harris was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:28 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 7,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000002 · wk-form4_1704320872.xml · nonDerivative · entry 1 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,955 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the January 1, 2024 vesting of restricted stock. F2 · balance_after: This balance includes 514 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantPerformance Stock Unit · Derivative | 21,204 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000050 · wf-form4_168418471268571.xml · derivative · entry 5 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires not disclosed F6 · derivative.exercise_date: On May 11, 2023, Ms. Harris was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F5 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 21,204 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000050 · wf-form4_168418471268571.xml · derivative · entry 4 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires not disclosed F4 · derivative.exercise_date: On May 11, 2023, Ms. Harris was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F5 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 39,683 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001077183-23-000050 · wf-form4_168418471268571.xml · derivative · entry 3 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,683 Underlying: Common Stock · 39,683 shares Expires 2030-05-11 F3 · derivative.exercise_date: On May 11, 2023, Ms. Harris was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 201,613 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001077183-23-000003 · wf-form4_167287197105833.xml · derivative · entry 2 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,613 Underlying: Common Stock · 201,613 shares Expires 2030-01-01 F2 · derivative.exercise_date: On January 1, 2023, Ms. Harris was granted 201,613 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 108,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000003 · wf-form4_167287197105833.xml · nonDerivative · entry 1 Harris Melody · CIK 0001880847 · President, Enterprise Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,225 F1 · shares: On January 1, 2023, Ms. Harris was granted 108,225 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:20 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantEmployee Stock Option (right to buy) · Derivative | 288,750 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001062993-22-006769 · form4.xml · derivative · entry 2 Harris Melody · CIK 0001880847 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,750 Underlying: Common Stock, par value $0.0001 · 288,750 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:20 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantCommon Stock | 48,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-006769 · form4.xml · nonDerivative · entry 1 Harris Melody · CIK 0001880847 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,125 Read SEC document |
| October 21, 2021 Filed Dec 13, 2021 17:10 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $11.53 | $0.00 |
DisclosureSEC source: 0001062993-21-012785 · form4.xml · derivative · entry 1 Harris Melody · CIK 0001880847 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock, par value $0.0001 · 500,000 shares Expires 2031-10-20 F1 · derivative.exercise_date: 25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.